ZYME   $6.43  0.62% Market Closed

Zymeworks Inc
Last Events:

2023-03-29 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-03-29 Trend Power changed from almost flat to strong.

2023-03-29 Trend changed from turning up to down and flat.

2023-03-29 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-03-29 Trend Power changed from strong to almost flat.

2023-03-29 Trend changed from down and flat to turning up.

2023-03-28 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-03-28 Trend Power changed from almost flat to strong.


Current temperature: 1.41
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 4.75
Target: 12.31
High with 50% probability: 9.74
Analyst Recommendations:
Number of estimates 12
Target Price Mean 12.31
Mean unverified/preliminary 12.31 / 12.31
Target Price Low / High 7.00 / 21.00
Median / STD DEV 10.50 / 5.03
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd Sell Sell Sell
stoch Sell Sell -
ma20 Sell - -
ma50 - Sell -
ma100 Sell - -
Candlestick PatternMarch 28, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN CA98985W1023
ceo Mr. Kenneth H. Galbraith C.A.
Website https://www.zymeworks.com
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.